Tags

Type your tag names separated by a space and hit enter

Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma.
Respir Med. 2013 Aug; 107(8):1152-63.RM

Abstract

PURPOSE

Evaluate the effect of the marine lipid fraction of the New Zealand green-lipped mussel (Perna canaliculus) PCSO-524 (Lyprinol/Omega XL), rich in omega-3 fatty acids, on airway inflammation and the bronchoconstrictor response to eucapnic voluntary hyperpnea (EVH) in asthmatics.

METHODS

Twenty asthmatic subjects, with documented HIB, participated in a placebo controlled double-blind randomized crossover trial. Subjects entered the study on their usual diet and were then placed on 3 weeks of PCSO-524 or placebo supplementation, followed by a 2 week washout period, before crossing over to the alternative diet. Pre- and post-eucapnic voluntary hyperpnea (EVH) pulmonary function, fraction of exhaled nitric oxide (FENO), asthma symptom scores, medication use, exhaled breath condensate (EBC) pH, cysteinyl leukotrienes (cyst-LT), 8-isoprostane and urinary 9α, 11β-prostaglandin (PG)F2 and Clara (CC16) protein concentrations were assessed at the beginning of the trial and at the end of each treatment period.

RESULTS

The PCSO-524 diet significantly reduced (p < 0.05) the maximum fall in post-EVH FEV1 (-8.4 ± 3.2%) compared to usual (-19.3 ± 5.4%) and placebo diet (-22.5 ± 13.7%). Pre- and post- EVH EBC cyst-LT and 8-isoprostane, and urinary 9α, 11β-PGF2 and CC16 concentrations were significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet. EBC pH and asthma symptom scores were significantly improved (p < 0.05) and rescue medication use significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet.

CONCLUSION

PCSO-524 (Lyprinol)/Omega XL) may have beneficial effects in HIB and asthma by serving as a pro-resolving agonist and/or inflammatory antagonist.

Authors+Show Affiliations

School of Public Health-Bloomington, Department of Kinesiology, Human Performance and Exercise Biochemistry Laboratory, 1025 E. 7th St. SPH 112, Bloomington, IN 47404, USA. tmickleb@indiana.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23660397

Citation

Mickleborough, Timothy D., et al. "Marine Lipid Fraction PCSO-524 (lyprinol/omega XL) of the New Zealand Green Lipped Mussel Attenuates Hyperpnea-induced Bronchoconstriction in Asthma." Respiratory Medicine, vol. 107, no. 8, 2013, pp. 1152-63.
Mickleborough TD, Vaughn CL, Shei RJ, et al. Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. Respir Med. 2013;107(8):1152-63.
Mickleborough, T. D., Vaughn, C. L., Shei, R. J., Davis, E. M., & Wilhite, D. P. (2013). Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. Respiratory Medicine, 107(8), 1152-63. https://doi.org/10.1016/j.rmed.2013.04.010
Mickleborough TD, et al. Marine Lipid Fraction PCSO-524 (lyprinol/omega XL) of the New Zealand Green Lipped Mussel Attenuates Hyperpnea-induced Bronchoconstriction in Asthma. Respir Med. 2013;107(8):1152-63. PubMed PMID: 23660397.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. AU - Mickleborough,Timothy D, AU - Vaughn,Cherissa L, AU - Shei,Ren-Jay, AU - Davis,Eliza M, AU - Wilhite,Daniel P, Y1 - 2013/05/07/ PY - 2013/02/12/received PY - 2013/04/09/revised PY - 2013/04/10/accepted PY - 2013/5/11/entrez PY - 2013/5/11/pubmed PY - 2014/2/19/medline KW - Asthma KW - Diet KW - Inflammation KW - Omega-3 fatty acids SP - 1152 EP - 63 JF - Respiratory medicine JO - Respir Med VL - 107 IS - 8 N2 - PURPOSE: Evaluate the effect of the marine lipid fraction of the New Zealand green-lipped mussel (Perna canaliculus) PCSO-524 (Lyprinol/Omega XL), rich in omega-3 fatty acids, on airway inflammation and the bronchoconstrictor response to eucapnic voluntary hyperpnea (EVH) in asthmatics. METHODS: Twenty asthmatic subjects, with documented HIB, participated in a placebo controlled double-blind randomized crossover trial. Subjects entered the study on their usual diet and were then placed on 3 weeks of PCSO-524 or placebo supplementation, followed by a 2 week washout period, before crossing over to the alternative diet. Pre- and post-eucapnic voluntary hyperpnea (EVH) pulmonary function, fraction of exhaled nitric oxide (FENO), asthma symptom scores, medication use, exhaled breath condensate (EBC) pH, cysteinyl leukotrienes (cyst-LT), 8-isoprostane and urinary 9α, 11β-prostaglandin (PG)F2 and Clara (CC16) protein concentrations were assessed at the beginning of the trial and at the end of each treatment period. RESULTS: The PCSO-524 diet significantly reduced (p < 0.05) the maximum fall in post-EVH FEV1 (-8.4 ± 3.2%) compared to usual (-19.3 ± 5.4%) and placebo diet (-22.5 ± 13.7%). Pre- and post- EVH EBC cyst-LT and 8-isoprostane, and urinary 9α, 11β-PGF2 and CC16 concentrations were significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet. EBC pH and asthma symptom scores were significantly improved (p < 0.05) and rescue medication use significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet. CONCLUSION: PCSO-524 (Lyprinol)/Omega XL) may have beneficial effects in HIB and asthma by serving as a pro-resolving agonist and/or inflammatory antagonist. SN - 1532-3064 UR - https://www.unboundmedicine.com/medline/citation/23660397/Marine_lipid_fraction_PCSO_524__lyprinol/omega_XL__of_the_New_Zealand_green_lipped_mussel_attenuates_hyperpnea_induced_bronchoconstriction_in_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(13)00139-X DB - PRIME DP - Unbound Medicine ER -